Klaus Breiner

Klaus is a founding and managing partner of Pureos and has been a venture capital investor since 2001, involved with life science companies across different regions, stages, and types. Prior to Pureos, he was a senior investment advisor for private equity at Bellevue Asset Management. Bio-pharmaceutical companies that Klaus has invested in include AM-Pharma, Alpex Pharma, Cadence Pharmaceuticals, Glycart Biotechnology, Hummingbird Bioscience, ImCheck Therapeutics, and Vaximm. Prior to venture capital, Klaus was a researcher at ETH Zurich and a business consultant at Booz Allen & Hamilton. Klaus holds an MA in chemistry from the University of North Carolina, Chapel Hill, and a Ph.D. in molecular biology from the University of Heidelberg (ZMBH).